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Abstract 
Background: In March 2020, the government of Uganda implemented a strict lockdown policy in response to the 
COVID‑19 pandemic. Interrupted time series analysis (ITSA) was performed to assess whether major changes in outpa‑
tient attendance, malaria burden, and case management occurred after the onset of the COVID‑19 epidemic in rural 
Uganda.
Methods: Individual level data from all outpatient visits collected from April 2017 to March 2021 at 17 facilities were 
analysed. Outcomes included total outpatient visits, malaria cases, non‑malarial visits, proportion of patients with 
suspected malaria, proportion of patients tested using rapid diagnostic tests (RDTs), and proportion of malaria cases 
prescribed artemether‑lumefantrine (AL). Poisson regression with generalized estimating equations and fractional 
regression was used to model count and proportion outcomes, respectively. Pre‑COVID trends (April 2017‑March 
2020) were used to predict the’expected’ trend in the absence of COVID‑19 introduction. Effects of COVID‑19 were 
estimated over two six‑month COVID‑19 time periods (April 2020‑September 2020 and October 2020–March 2021) by 
dividing observed values by expected values, and expressed as ratios.
Results: A total of 1,442,737 outpatient visits were recorded. Malaria was suspected in 55.3% of visits and 98.8% of 
these had a malaria diagnostic test performed. ITSA showed no differences between observed and expected total 
outpatient visits, malaria cases, non‑malarial visits, or proportion of visits with suspected malaria after COVID‑19 onset. 
However, in the second six months of the COVID‑19 time period, there was a smaller mean proportion of patients 
tested with RDTs compared to expected (relative prevalence ratio (RPR) = 0.87, CI (0.78–0.97)) and a smaller mean 
proportion of malaria cases prescribed AL (RPR = 0.94, CI (0.90–0.99)).
Conclusions: In the first year after the COVID‑19 pandemic arrived in Uganda, there were no major effects on malaria 
disease burden and indicators of case management at these 17 rural health facilities, except for a modest decrease 
in the proportion of RDTs used for malaria diagnosis and the mean proportion of malaria cases prescribed AL in the 
second half of the COVID‑19 pandemic year. Continued surveillance will be essential to monitor for changes in trends 
in malaria indicators so that Uganda can quickly and flexibly respond to challenges imposed by COVID‑19.
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Background
Significant progress in malaria control has been realized 
in sub-Saharan Africa over the last two decades follow-
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[1]. At the start of the COVID-19 pandemic, there was 
concern that progress in the fight against malaria would 
be reversed due to interruption of malaria control inter-
ventions and overwhelmed health care systems, with 
some modelling studies suggesting that malaria mor-
bidity and /or mortality may double due to COVID-19 
[2–4]. In Uganda, malaria is endemic in over 95% of the 
country and the leading cause of morbidity and mortality, 
accounting for 30–50% of outpatient visits, 15–20% of all 
hospital admissions, and up to 20% of all hospital deaths 
[5]. While successes have been registered in malaria con-
trol in the country in the last decade, including increased 
coverage of control interventions and reductions in the 
overall disease burden [6, 7], there is concern that these 
achievements may be reversed by the global COVID-19 
pandemic.
The World Health Organization (WHO) declared 
COVID-19 a global pandemic on 11 March 2020 [8]. 
The Government of Uganda swiftly implemented strict 
restrictions and diverted personnel and resources to min-
imize the spread of SARS-CoV-2 and mitigate the eco-
nomic burden of the pandemic. On 18 March, 2020, mass 
gatherings were suspended, and a 14-day quarantine was 
imposed on all travellers arriving in Uganda [8]. When 
the country registered its first confirmed case on  21st 
March 2020, additional restrictions were implemented, 
including: (1) closure of borders except for cargo and 
goods on 21 March, 2020; (2) suspension of public trans-
port and restrictions on movement of private vehicle on 
25 March, 2020; (3) mandatory testing of truck drivers on 
10 April, 2021; (4) a national lockdown and curfew from 
19.00 to 06.30 on 30 March, 2020, initially for 14 days but 
eventually extended to 26 May, 2020, and (5) closure of all 
schools [8]. Despite these measures, Uganda’s COVID-
19 cases progressively increased over the period with 
the country registering its first 100 confirmed cases on 6 
May, 2020, first death on 23 July, 2020, first 1000 cases on 
9 June, 2020 and first wave peak in December 2020.
Although lockdowns have been shown to minimize the 
spread of COVID-19 [9–11], they may have major reper-
cussions on malaria treatment and prevention including 
decreased access to health care, interruption of service 
delivery, and disruption of delivery of malaria control 
interventions such as long-lasting insecticide treated net 
(LLIN) or indoor residual spraying (IRS) campaigns. In 
addition, an increase in the incidence of fever cases due 
to COVID-19 may lead to an increase in the number of 
suspected malaria cases presenting at health facilities, 
increasing demand for malaria diagnostics, and poten-
tially leading to over diagnosis and overtreatment of 
malaria and/or a shortage of diagnostics. Indeed, a mod-
elling study by WHO predicted that in the ‘worst case’ 
scenario where LLINs campaigns were cancelled and 
access to effective antimalarial treatment was severely 
disrupted, malaria deaths could increase by > 200% in 
Uganda as result of the COVID-19 pandemic [12].
Interrupted time series analysis (ITSA) is a quasi-
experimental study design that can be used to estimate 
causal effects using observational data. It is often used 
to evaluate the effectiveness of population-level health 
interventions that have been implemented at a clearly 
defined point in time [13–16]. ITSA has also been used 
to evaluate the effect of an unplanned event on health 
outcomes, such as the effect of the late 2000s financial 
crisis on suicides in Spain [17]. A key assumption of 
ITSA is that the pre-intervention trend would provide a 
suitable estimate of the post-intervention trend had the 
intervention never occurred. In this study, interrupted 
time series analysis was used to assess the effect of the 
COVID-19 pandemic in Uganda on malaria disease bur-
den and case management at 17 public health facilities 
across rural Uganda using three years of pre-COVID data 
to model the baseline trend. Results from the study will 
improve our understanding of the effect of COVID-19 on 




The study utilized data collected at 17 Malaria Reference 
Centres (MRCs) located in rural settings from April 2017 
through March 2021 (Fig.  1). MRCs are high-volume, 
level III/IV, public health facilities located through-
out Uganda in areas with varying malaria transmission 
intensities. MRCs were first established in 2006 by the 
Uganda Malaria Surveillance Project (UMSP), a project 
led by Makerere University, University of California, 
San Francisco (UCSF), and Infectious Diseases Research 
Collaboration (IDRC) groups, in collaboration with the 
Uganda Ministry of Health. Details of the MRCs have 
been described elsewhere [18] but briefly, there are cur-
rently 70 MRCs collecting high quality, individual level 
data from all patients presenting at the outpatient clin-
ics of the facilities. Of the 70 MRCs, 17 were selected for 
this analysis based on the following criteria: (1) MRC 
was opened and data collection commenced before Janu-
ary 2017; and (2) MRC had less than 5% missing data on 
four of the variables (suspected malaria case, malaria test 
done, malaria test result recorded, type of malaria test 
done).
At each MRC, patient data are recorded in standard-
ized health management information system (HMIS) 
registers (HMIS 002—outpatient register) at the out-
patient clinics. Data are  transcribed from the registers 
into Microsoft Access databases by on-site records 
officers. Data collected include patient demographics, 
Page 3 of 11Namuganga et al. Malaria Journal          (2021) 20:475  
village of residence, history of fever, whether a malaria 
diagnostic test was performed, type of malaria test 
done (rapid diagnostic test (RDT) vs microscopy), 
results of laboratory tests, diagnoses given, and treat-
ments prescribed. Data are not collected on whether a 
patient receives or is adherent to the prescribed treat-
ment. On average, over 1,400 patient visits and 1,000 
suspected malaria cases tested are captured monthly 
at each MRC. Adherence to malaria case management 
guidelines is emphasized and supported at the MRCs 
through training, onsite mentorship and support from 
regional surveillance assistants, regular continuous 
medical education sessions, and monthly data analysis 
and feedback sessions for on-site health workers. Rou-
tine data quality assessments are undertaken at each 
site to ensure collection of high quality data in terms of 
completeness and accuracy.
Laboratory procedures
All patients suspected to have malaria are routinely sent 
to an onsite laboratory for confirmatory testing using 
either malaria microscopy or malaria RDT kits. Malaria 
microscopy at the MRCs is conducted by skilled labora-
tory personnel and generally reserved for when RDTs are 
not available or of limited stock and upon request from a 
clinician. Quality control for malaria microscopy is con-
ducted monthly at each site by a laboratory team who 
are part of the core UMSP team. They also provide onsite 
mentorship for site laboratory personnel to ensure high 
quality malaria testing.
Malaria control interventions
Malaria control activities at the MRCs during the study 
period included: (1) malaria case management as per 
the Uganda National Treatment Guidelines [19] which 




Fig. 1 Map of Uganda with the 17 Malaria Reference Centres included in the analysis
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recommends artemether-lumefantrine (AL)as first-line 
therapy; (2) promotion of intermittent preventive treat-
ment during pregnancy; and 3) universal distribution of 
free LLINs. Two national LLIN distribution campaigns 
were conducted during the study period, in 2017–18 and 
2020–2021 (Figs. 1 and 2). The status of IRS campaigns 
varied across the sites included in this study as shown 
in Fig. 2; three sites were in districts that never received 
IRS; IRS was discontinued in 2017 in districts where nine 
sites were located, and the remaining five sites were in 
districts that had sustained IRS campaigns throughout 
the study period.
Statistical analysis
ITSA, using segmented regression, were conducted to 
estimate the impact of the COVID-19 epidemic on key 
malaria indicators. Data from all 17 sites from April 2017 
through the end of March 2021 were included in the anal-
ysis. The study period included three years pre-COVID 
and one year after the arrival of COVID-19 in Uganda, 
with the start of the COVID-19 time period defined as 
1 April, 2020 (Fig.  2). Outcomes for the ITSA included 
number of total outpatient visits, number of non-malarial 
visits (visits in which malaria was not diagnosed), malaria 
visits (visits in which a laboratory-confirmed diagnosis of 
malaria was made, synonymous with malaria cases), pro-
portion of all patient visits with suspected malaria, pro-
portion of patients tested using RDTs, and proportion of 
patients with confirmed malaria prescribed AL.
In the segmented regression model, the baseline trend 
during the pre-COVID-19 period and the slope change 
following the arrival of COVID-19 in the country are 
modelled. To estimate the counterfactual (COVID-
19 time period) trend, the slope change is set to 0. The 
generalized segmented regression model is as follows: 
Yht = β0 + β1T  + β2Pt  + β3Ct + β4Rht , where Yht rep-
resents the outcome recorded at the health facility h in 
month t, β0 is the intercept at the start of the study (t = 0), 
T is a linear term indicating the time in months since the 
start of the study observation period (models the pre-
COVID trend), Pt is a linear term indicating the months 
since the start of the COVID-19 time period (models 
the observed change in trend after COVID onset), Ct is 
a linear term indicating calendar month fixed effects 
(e.g., January, February, etc.) to model seasonality), and 
Rht is a vector of monthly rainfall data (mm) lagged by 
one month and averaged across the district-level. Pois-
son regression was used to model count outcomes using 
a generalized estimating equation (to account for clus-
tered observations between sites) with an autoregressive 
of order one (ar1) correlation structure (to account for 
serial autocorrelation of error terms of outcomes of adja-
cent time periods within-sites). Fractional regression was 
used to model proportional outcomes.
For ITSA models that included malaria outcomes, 
additional linear terms representing the number of 
months since LLIN distribution and the round of IRS 
were included to adjust for time-varying confounding. 
Based on surveillance data from these sites, LLIN cam-
paigns were assumed to confer 24 months of protection, 
whereas IRS campaigns (which used Actellic or Sum-
ishield-based insecticides) were assumed to provide up to 
a year of protection. For Poisson models, the underlying 
population was assumed constant throughout the study 
period and thus no offset term was included.
Models were then used to predict the unobserved 
counterfactual values (i.e., ‘expected’ values in absence 
of COVID-19) for each health facility in each month 
(i.e., monthly number of events or proportions had 
the epidemic not occurred) by setting Pt to zero. For 
count outcomes, incidence rate ratios (IRR) were cal-
culated by summing the outcomes across the first and 
second six months after COVID-19 started in Uganda 
and dividing the observed by the expected values. For 
Fig. 2 Timeline of malaria interventions and COVID‑19 epidemic in Uganda
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proportion outcomes, relative prevalence ratios (RPR) 
were calculated by averaging the monthly proportions 
across the two six-month COVID-19 time periods and 
dividing the observed by expected values. 95% con-
fidence intervals were obtained using a 1,000 block, 
percentile-bootstrapping procedure, where sites were 
resampled with replacement.
Results
From April 2017 through March 2021, 1,442,737 patient 
visits were recorded at the 17 MRCs (Table  1). The 
median age of patients was 23  years, and the majority 
(67%) were female. Malaria was suspected in 798,270 
(55.3%) of all patient visits, and almost all (98.8%) 
patients with suspected malaria had a malaria diagnos-
tic test done. RDTs were the most common laboratory 
diagnostic tool used to test patients for malaria (83.8%), 
although this varied by site (range: 24.0 to 99.8%). 
Overall, malaria test positivity rate was 53.1%, ranging 
from 14.1 to 69.8% at individual MRCs. Most patients 
with confirmed malaria were prescribed AL (93%), the 
recommended first line treatment for uncomplicated 
malaria in Uganda. A detailed description of the study 
population stratified by site and status of IRS is pre-
sented in Table 1.
Trends in disease burden and case management 
over the study period
Over the four-year study period, a single annual peak 
was observed in the number of monthly outpatient visits, 
with the highest number of visits observed during mid-
year of 2019 (> 2,500 visits, Fig. 3A). The monthly trend 
in the number of outpatient visits for non-malarial illness 
was declining at a steady pace before the COVID-19 epi-
demic (Fig.  3B). The number of malaria visits followed 
a similar trend to that of the total outpatient visits, with 
peaks in these occurring simultaneously (Fig. 3C). Simi-
lar trends were observed with the proportion of sus-
pected malaria cases (Fig. 3D). The proportion of patients 
tested with RDT each month remained consistently high 
(> 70%) and almost constant throughout the study period, 
except in 2018 when the proportion reached > 90% and in 
2021 when the proportion fell below 70% (Fig.  3E). The 
proportion of confirmed malaria cases prescribed AL 
(Fig.  3F) was consistently high, remaining > 90% from 
late 2019 through 2020, before a decline was observed 
in 2021. The mean proportion of patients with suspected 
malaria who received a diagnostic test is not shown in 
Fig.  3 because it remained consistently high across all 
study time points (Additional file 1:  Fig. S1) and there-
fore a formal ITSA was not performed.
Table 1 Cumulative totals of key malaria indicators stratified by malaria reference centre (MRC) from April 2017 to March 2021
*Includes only those with laboratory confirmed malaria

































Kasambya 59,574 20.7 67.5 44,118 (74.1) 42,830 (97.1) 24,522 (57.3) 19,100 (44.6) 18,801 (98.4)
Kihihi 79,561 25.2 65.6 46,207 (58.1) 46,153 (99.9) 11,061 (24.0) 17,322 (37.5) 16,099 (92.9)
Opia 57,879 17.7 63.6 46,586 (80.5) 46,335 (99.5) 46,270 (99.8) 28,378 (61.2) 28,091 (99.0)
IRS discontin‑
ued
Aduku 102,761 24.7 69.9 58,404 (56.8) 57,157 (97.9) 36,702 (64.2) 31,723 (55.5) 30,910 (97.4)
Anyeke 108,612 24.6 66.3 52,820 (48.6) 51,765 (98.0) 46,143 (89.1) 35,056 (67.7) 32,089 (91.5)
Aboke 81,626 24.2 68.6 50,075 (61.3) 49,740 (99.3) 45,908 (92.3) 34,696 (69.8) 32,920 (94.9)
Awach 110,328 20.7 69.2 61,252 (55.5) 59,357 (96.9) 58,183 (98.0) 38,343 (64.6) 35,956 (93.8)
Lalogi 110,585 21.8 68.7 67,335 (60.9) 67,095 (99.6) 65,652 (97.8) 38,572 (57.5) 35,315 (91.6)
Patongo 77,556 20.4 66.2 54,394 (70.1) 53,794 (98.9) 51,244 (95.3) 29,858 (55.5) 28,619 (95.9)
Atiak 87,872 19.8 65.5 49,529 (56.4) 48,685 (98.3) 48,477 (99.6) 32,894 (67.6) 30,530 (92.8)
Padibe 89,262 21.3 66.5 56,985 (63.8) 56,849 (99.8) 55,864 (98.3) 35,023 (61.6) 32,484 (92.8)
Namokora 92,605 20.6 65.0 64,242 (69.4) 63,930 (99.5) 57,983 (90.7) 36,163 (56.5) 32,216 (89.2)
IRS sustained Nagongera 77,735 23.3 65.8 27,667 (35.6) 27,623 (99.8) 14,286 (51.7) 3,891 (14.1) 3,459 (88.9)
Amolatar 71,440 26.5 65.8 19,231 (26.9) 19,132 (99.5) 16,302 (85.2) 6173 (32.3) 5417 (87.8)
Dokolo 115,297 27.1 68.6 42,046 (36.5) 41,847 (99.5) 38,555 (92.1) 13,124 (31.4) 11,617 (88.5)
Orum 47,440 26.5 65.5 26,265 (55.4) 26,252 (100) 16,128 (61.4) 10,162 (38.7) 7,799 (76.7)
Alebtong 72,604 27.8 70.1 31,114 (42.9) 30,424 (97.8) 28,173 (92.6) 8,379 (27.5) 7,726 (92.2)
All sites combined 1,442,737 23.0 67.0 798,270 (55.3) 788,988 (98.8) 661,453 (83.8) 418,830 (53.1) 390,048 (93.1)
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Impact of COVID‑19 on disease burden and case 
management
Figure 3 shows that, for all outcomes except proportion 
of patients tested with RDT and proportion of malaria 
cases prescribed AL, there was no statistically significant 
change in the 12-month COVID-19 time period (April 
2020- March 2021); observed monthly values fell within 
the 95% confidence interval of the expected values. This 
held true for total outpatient visits, malaria and non-
malaria visits, and proportion of patients suspected to 
have malaria. However, for proportion of patients tested 



























































































Proportion Malaria Cases Prescribed Artemether-LumefantrineF
Fig. 3 Observed and expected A total number of visits, B non‑malaria visits, C visits where malaria was diagnosed, D mean proportion of 
suspected malaria cases, and E mean proportion of patients tested using RDT by month, and F mean proportion of malaria cases prescribed 
artemether‑lumefantrine. The grey ribbon represents the bootstrapped 95% confidence interval of the model. Vertical red line represents the start 
of the COVID‑19 time‑period on 1 April 2020. Vertical black dashed line represents the 6‑month midpoint of the COVID‑19 time period (1 October, 
2020)
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AL, observed values were lower than expected in the 
last six months of observation based on pre-COVID 
trends. Effect estimates across all measured outcomes 
are presented in Table 2, stratified into the first and sec-
ond six months of the COVID-19 time intervals. In the 
first six months after the onset of COVID-19 epidemic, 
during which the lockdown was strictest, there were no 
significant differences in the observed versus expected 
numbers of total visits (196,300 vs 216,822; IRR = 0.91 
(0.82–1.00)), malaria cases (75,825 vs 82,884; IRR = 0.92 
(0.76–1.14)), and non-malarial visits (120,475 vs 123,902; 
IRR = 0.97 (0.92–1.04)). There were also no significant 
differences in the mean proportion of suspected malaria 
cases, mean proportion tested with RDT, or mean pro-
portion prescribed AL.
Over the second six months of the COVID-19 time 
period (October 2020-March 2021), during which lock-
down restrictions were eased despite increasing COVID-
19 cases in the country, there were again no significant 
differences observed versus expected numbers total vis-
its [187,573 vs 186,136; RR 1.01 (0.81–1.23)], malaria 
cases [60,032 vs 50,050, RR 1.20 (0.75, 1.84)] and non-
malarial visits [127,541 vs 118,890; RR 1.07 (0.95–1.21)]. 
There was also no difference in the proportion of sus-
pected malaria cases. However, for the mean proportion 
of patients tested with RDTs, there was a significantly 
smaller mean proportion of patients tested with RDTs 
compared to expected [80.3% vs 92.2%; RR 0.87 (0.78, 
0.97)]. In addition, there was a smaller mean proportion 
of malaria cases prescribed AL compared to expected, 
(89.1% vs 94.4%; RPR = 0.94 (0.90, 0.99)). This was likely 
due to an increase in the percentage of patients with 
laboratory confirmed malaria that received a prescrip-
tion of dihydroartemisinin-piperaquine (DP); this per-
centage rose from 0.04% in the pre-COVID-19 period to 
0.3% from April 2020-September 2020 and to 3.7% in the 
period from October 2020 through March 2021.
Discussion
This study evaluated the impact of the COVID-19 pan-
demic on the number of outpatient visits, malaria disease 
burden and case management practices between April 
2020 and March 2021 using routine surveillance data 
collected at 17 high-volume, public, outpatient facilities 
in areas of varying malaria transmission across Uganda. 
In this study the number of outpatient visits, malaria 
cases, and non-malaria visits, as well as most indicators 
of malaria case management, did not reflect any signifi-
cant changes in the first year following the onset of the 
COVID-19 epidemic. However, from October 2020 
through March 2021, a modestly lower mean propor-
tion of suspected malaria patients received an RDT for 
malaria diagnosis compared to what was expected for 
that period in the absence of COVID-19. Notably, this 
difference was not reflected by a change in the propor-
tion of patients with suspected malaria who underwent 
diagnostic testing, as microscopy was available as an 
alternative to RDTs. A similar trend was observed in the 
last six months of observation for the mean proportion of 
malaria cases prescribed AL.
The emergence and rapid spread of COVID-19 across 
the world has created massive global disruptions on 
health systems, social services, and economic activ-
ity [20]. The disruption in health services is expected to 
be magnified in sub-Saharan Africa to a greater degree 
than in other regions due to relatively weak health ser-
vice infrastructures, low clinician to population ratios, 
limited laboratory capacity, and a higher burden of other 
infectious diseases [21]. Delivery of malaria preventive 
measures and care services are some of the activities 
most likely to be affected by the epidemic given the high 
prevalence of malaria in the region [22]. Indeed, there are 
predictions that malaria cases will increase, and malaria-
related mortality may nearly double, decelerating any 
gains attained in the last decade [2, 3, 12, 23]. Uganda, 
Table 2 Estimates of the impact of COVID‑19 epidemic on disease burden during the first and second six months of the COVID‑19 
time period
a Estimates reported as the total number of visits or mean proportion during the 1-year post-policy period
b For visit outcomes, this represents an incidence rate ratio; for proportions, a relative percent ratio. Assumed a constant population at-risk over the study period
Outcomes April 2020‑September 2020 October 2020‑March 2021
Observeda Expecteda Ratio [95%  CI]b Observeda Expecteda Ratio [95%  CI]b
Total number of outpatient visits 196,300 216,822 0.91 [0.82, 1.00] 187,573 186,136 1.01 [0.81,1.23]
No of visits with a malaria diagnosis 75,825 82,8842 0.92 [0.76, 1.14] 60,032 50,050 1.20 [0.75, 1.84]
Number of non‑malaria visits 120,475 123,902 0.97 [0.92, 1.04] 127,541 118,890 1.07 [0.95, 1.21]
% Suspected/visits 61.9% 64.1% 0.97 [0.93, 1.04] 61.6% 61.9% 0.99 [0.89,1.22]
% Tested with RDT 85.4% 88.3% 0.97 [0.91, 1.01] 80.3% 92.2% 0.87 [0.78,0.97]
% Malaria cases prescribed AL 94.2% 95.2% 0.99 [0.98, 1.00] 89.1% 94.4% 0.94 [0.90, 0.99]
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one of the highest malaria burden countries in sub-Saha-
ran Africa, was predicted to be one of the countries most 
likely to be affected by the COVID-19 pandemic. Accord-
ing to a WHO modelling study, by the end of 2020 in a 
scenario where LLIN campaigns are not implemented 
and LLIN continuous distributions and access to effec-
tive anti-malarial treatment are reduced by up to 75%, 
malaria deaths could increase by 200% in Uganda [12]. A 
study by Bell et al. predicted less disastrous effects result-
ing from a widespread COVID-19 outbreak compared to 
the impact of lockdowns on malaria programmes [24].
However, contrary to those worst-case scenarios, these 
data suggest that despite travel restrictions and other 
lockdown measures, access to care and malaria case 
management were largely unaffected by the COVID-
19 pandemic in the first year after it was confirmed in 
Uganda. This could be because 75% of the population in 
Uganda resides in rural areas where patients seeking care 
either walk or ride bicycles to the health facilities [25], 
making access to care possible even with restrictions to 
motor vehicle movements. In addition, the health sys-
tem is structured in such a way that most of the health 
care staff are housed at or near the facilities; furthermore, 
travel permits were provided for health workers who 
needed to travel long distances to their duty stations, pre-
venting the staff shortages that would likely have limited 
access to malaria care. Finally, planned malaria control 
activities, including the mass LLIN distribution cam-
paign (implemented between June 2020 and March 2021) 
and IRS rounds, were successfully implemented despite 
the pandemic.
In addition, the outbreak was expected to increase 
fever cases because COVID-19 and malaria both pre-
sent with fevers. However, community transmission of 
COVID-19 remained low during the first year following 
the outbreak; this may explain the fact that this analysis 
showed no increase in non-malarial visits or proportion 
of cases with suspected malaria. However, a decrease in 
the proportion of patients tested for malaria using RDTs 
was observed. This may be because of global supply 
chain issues that resulted in local stock-outs of RDTs. In 
the last year, there was a noted global decline in malaria 
RDT production and supply, with manufactures shift-
ing in focus from RDTs to COVID-19 point-of-care tests 
[26, 27]. Importantly, the decrease in proportion of RDTs 
used as a laboratory diagnostic did not affect whether 
or not patients received a diagnostic test for suspected 
malaria because microscopy was available as an alterna-
tive diagnostic at the MRCs.
There was also a modest decrease in the mean propor-
tion of malaria cases prescribed AL, the standard of care 
for the treatment of uncomplicated malaria in Uganda, 
seen in the last six months of observation. Given that a 
major limitation of interrupted time series analyses is 
that a change in a time series could be due to another fac-
tor that co-occurs with the intervention studied (in this 
case the arrival of the COVID-19 pandemic in Uganda), 
it was prudent to investigate whether there were any 
other changes affecting AL use at health facilities during 
the COVID-19 time period. Recently, Uganda’s Minis-
try of Health secured funding to procure DP for use as 
second-line treatment for uncomplicated malaria in the 
event of treatment failure for patients using AL, and for 
prescription to all patients with severe malaria follow-
ing completion of three intravenous artesunate doses 
[28]. Therefore, from 2020 to-date, DP has been avail-
able at some public health facilities for use as a second-
line treatment for patients with treatment failure due to 
AL and all patients diagnosed with severe malaria fol-
lowing completion of artesunate treatment, leading to 
an increase in the number of patients prescribed DP as 
described in the results. The decrease in prescriptions of 
AL observed in the last six months of the study may not 
be due to a decrease in supply or availability of AL due 
to the COVID-19 pandemic but instead due to chang-
ing prescription practices in response to policy changes 
regarding DP. There was no direct data on AL stock cap-
tured at these health facilities over the timeframe of the 
analysis, and as such this study was unable to conclu-
sively attribute this decline in AL use to supply chain dif-
ficulties caused by the COVID-19 pandemic.
Other studies in similarly resource-restricted settings 
have shown varied impacts of the COVID-19 pandemic 
on malaria burden and deaths. A brief report published 
regarding patients at one health facility in Sierra Leone 
showed a decrease in the number of malaria cases diag-
nosed in children younger than five years of age in April 
2020 compared to April 2019, but this had recovered 
by May 2020 [29]. However, this study was at a single 
health facility, did not account for seasonality, and only 
observed three months of the COVID-19 time period. A 
larger study in Zimbabwe, which utilized routine malaria 
surveillance data collected from all public and private 
health facilities from January 2017 to June 2020, found an 
excess of over 30,000 malaria cases from January to June 
2020 compared to an average over the same period from 
2017, 2018, and 2019 data [30]. This study also found that 
the number of malaria deaths recorded from January to 
June 2020 exceeded the annual totals for 2018 and 2019. 
However, while they describe these increases by com-
paring numbers from January 2020 to June 2020 to prior 
data, they do not make any statistical inference regarding 
their findings and note the limitations of routine surveil-
lance data regarding data quality. A particular strength of 
the study presented here is the use of a quasi-experimen-
tal, interrupted time series study design which accounted 
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for pre-COVID trends, other factors such as seasonality, 
rainfall, differences in study site, and concurrent LLIN 
and IRS campaigns, to predict unobserved counterfac-
tual outcomes one year after the onset of COVID-19. In 
addition, the MRCs included had a full three years of pre-
COVID data that had undergone a supervised data clean-
ing process, resulting in less than 5% missing data.
Several limitations of this study are worth noting. Data 
from only 17 MRCs was used for this study because high-
quality data over a sufficient length of pre-intervention 
time are important to establish a baseline trend in a 
time series analysis, and most MRCs did not have three 
years of pre-COVID-19 data. The majority of the MRCs 
included in the study are in rural areas and, as seen in 
Fig. 1, are not evenly distributed throughout the country. 
Therefore, this study’s findings may not be generalizable 
to the entirety of the country, especially to geographic 
areas not represented in the study and to more urban 
areas. Though similar outcomes are available through 
national health management information systems 
(HMIS) databases, HMIS data have been shown to suffer 
from increased ‘missingness’ and quality control prob-
lems [31, 32] and to provide robust estimates these data 
were not included. In addition, the impact of the COVID-
19 pandemic on malaria mortality was not assessed, as 
these data were not available. This study was also limited 
in its ability to assess what drugs patients actually took 
since data were only available on antimalarial prescrip-
tion practices and not whether anti-malarial drugs were 
actually available and administered.
Importantly, COVID-19 cases were still relatively low 
in Uganda during the period this study was conducted, 
and it is likely that the impact of the COVID-19 pan-
demic on malaria indicators may change as community 
transmission increases, especially with the Delta variant 
now in the country. This is already being observed as the 
number of cases between March and July 2021 has dou-
bled compared to what was observed between March 
and July 2020 (90,656 versus 40,962) [33]. Thus, the con-
clusions drawn in this study only reflect the effect of the 
COVID-19 pandemic on malaria indicators in the first 
year after arrival of COVID-19 in Uganda. The surge in 
cases caused by the Delta variant resulted in a second 
government-imposed lockdown in June 2021. Therefore, 
additional studies on the impact of the epidemic and the 
effect of lockdown policies will be required.
Finally, though ITSA is known to be a robust method 
of utilizing observational longitudinal data for esti-
mating causal effects [14, 16], the study cannot rule 
out that estimates may have been subject to unmeas-
ured confounding. For the AL outcome in particular, 
other health policy changes may be responsible for 
the decline in prescriptions of AL seen in the second 
six months of the COVID-19 time period. However, 
this does not change the central finding, which showed 
very little effect of the COVID-19 pandemic on malaria 
burden and case management in the first year after 
the arrival of COVID-19 in Uganda. Furthermore, if 
the decline in RDT use is confirmed to be due to sup-
ply chain issues and stock-outs, this is critical feedback 
for the Ministry of Health, so that plans can be made to 
source additional RDTs and/or to support the availabil-
ity of microscopy at health facilities.
Conclusion
Utilizing routine surveillance data from 17 rural health 
facilities across Uganda, this study found the onset of 
the COVID-19 epidemic did not have major effects on 
malaria disease burden and indicators of case manage-
ment, except for a modest decrease in the mean pro-
portion of RDTs used for malaria diagnosis and the 
mean proportion of malaria cases prescribed AL in 
the second half of the COVID-19  year. However, con-
tinued surveillance will be essential to monitor for any 
changes in trends in malaria indicators due to the indi-
rect effects of the COVID-19 pandemic so that neces-
sary public health interventions can be instituted early 
to prevent increases in malaria morbidity and mortality. 
For example, now that a decrease in the usage of RDTs 
has been shown, it will be important to further investi-
gate the cause of this decline and implement solutions 
by sourcing additional RDT supplies or ensuring access 
to high-quality microscopy at all public health facilities.
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